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CHALLENGES IN THE USE OF SCALE-DOWN MODELS FOR UNDERSTANDING AND MITIGATING
PROCESS VARIATIONS OF A MONOCLONAL ANTIBODY PRODUCTION PROCESS
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Scale-down models are commonly used to execute process characterization studies, as well as to screen raw
materials and to conduct investigations in support of manufacturing operations. During the clinical manufacture
of a monoclonal antibody, consistent product quality was maintained; however, large variations in bioreactor
harvest titer (> 2X) were observed between lots. Root cause analysis of this variation did not establish a linkage
between culture performance and manufacturing execution or deviations. Further, small scale satellite reactor
performance displayed lesser variability; thereby eliminating seed train and raw materials as potential root
causes. Small scale investigations, using multiple scale-down models, were not able to reproduce the variability
in product titer, and other cell culture metrics, observed at large scale. However, these studies were able to
establish a correlation between cellular metabolism, feeding strategy and harvest titer. As a result, process
modifications have successfully been developed to obtain a more robust production bioreactor process while
maintaining product quality.

